Sirenas Receives Research Grant Totaling $1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS™

Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from nature`s chemistry, announced that it has received a new grant from the Bill & Melinda Gates Foundation to advance ATLANTIS™, the company`s proprietary drug discovery technology.  With today`s announcement, Sirenas has now received two research grant awards from the foundation totaling $1.68 M. 

ATLANTIS™ uses "big data" approaches to uncover the relationships between millions of natural small molecule metabolites and disease relevant biological assays. This process enables Sirenas to efficiently gain insights into the therapeutic potential of each molecule more rapidly than traditional drug discovery approaches. With the funds from the foundation, Sirenas will accelerate the use of ATLANTIS™, including the integration of machine learning approaches, to identify therapeutic candidates to treat widespread infectious diseases including tuberculosis and malaria.

"Sirenas is honored to be a long-time recipient of Bill & Melinda Gates Foundation funding to support breakthrough drug discovery approaches like ATLANTIS™ to uncover new ways to treat these debilitating infectious diseases," said Jake Beverage, PharmD., Co-Founder and CEO of Sirenas.  "Funds from this grant will broaden the use of our ATLANTIS™ technology, enhance our fundamental processes to enable efficient drug discovery, and deepen our focus on infectious diseases."  

Bob More, Managing Director of Alta Partners and a member of the board of Sirenas, added, "The grant capital from the foundation provides a creative and efficient approach to accelerate our drug discovery capabilities.  We look forward to collaborating with the foundation, who have brought unique skills to bear on sourcing and identifying new chemistry, on our shared goal to eradicate these infectious diseases from the globe."